Nothing Special   »   [go: up one dir, main page]

HUE060310T2 - Apoptosis-indukáló szerek - Google Patents

Apoptosis-indukáló szerek

Info

Publication number
HUE060310T2
HUE060310T2 HUE18787582A HUE18787582A HUE060310T2 HU E060310 T2 HUE060310 T2 HU E060310T2 HU E18787582 A HUE18787582 A HU E18787582A HU E18787582 A HUE18787582 A HU E18787582A HU E060310 T2 HUE060310 T2 HU E060310T2
Authority
HU
Hungary
Prior art keywords
apoptosis
inducing agents
inducing
agents
Prior art date
Application number
HUE18787582A
Other languages
English (en)
Inventor
Hongbin Liu
Yue Rong
Huajie Zhang
Zhifang Chen
Rui Tan
Chengxi He
Zhifu Li
Zuwen Zhou
Haohan Tan
kai Ran
Xianlong Wang
Zongyao Zou
Lihua Jiang
Yanxin Liu
Xingdong Zhao
Weibo Wang
Jiemin Fu
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd, Fochon Pharmaceuticals Ltd filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Publication of HUE060310T2 publication Critical patent/HUE060310T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE18787582A 2017-04-18 2018-04-17 Apoptosis-indukáló szerek HUE060310T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762486965P 2017-04-18 2017-04-18
US201762572417P 2017-10-14 2017-10-14

Publications (1)

Publication Number Publication Date
HUE060310T2 true HUE060310T2 (hu) 2023-02-28

Family

ID=63856416

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18787582A HUE060310T2 (hu) 2017-04-18 2018-04-17 Apoptosis-indukáló szerek

Country Status (21)

Country Link
US (2) US11091478B2 (hu)
EP (2) EP3612531B1 (hu)
JP (2) JP7085566B2 (hu)
KR (1) KR102630069B1 (hu)
CN (2) CN110546151B (hu)
AU (2) AU2018255621B2 (hu)
BR (1) BR112019021434A2 (hu)
CA (1) CA3057886A1 (hu)
DK (1) DK3612531T3 (hu)
ES (1) ES2927182T3 (hu)
HR (1) HRP20221158T1 (hu)
HU (1) HUE060310T2 (hu)
LT (1) LT3612531T (hu)
MX (2) MX2019012434A (hu)
PL (1) PL3612531T3 (hu)
PT (1) PT3612531T (hu)
RS (1) RS63603B1 (hu)
SI (1) SI3612531T1 (hu)
TW (1) TWI791511B (hu)
WO (1) WO2018192462A1 (hu)
ZA (1) ZA201906011B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018127130A1 (en) 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
RS63603B1 (sr) * 2017-04-18 2022-10-31 Shanghai Fochon Pharmaceutical Co Ltd Sredstva za indukciju apoptoze
IL272762B2 (en) 2017-08-23 2024-03-01 Newave Pharmaceutical Inc Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases
KR102738032B1 (ko) 2018-04-29 2024-12-05 베이진 엘티디 Bcl-2 억제제
WO2020041405A1 (en) * 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
WO2020140005A2 (en) * 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
NZ788615A (en) * 2019-12-06 2024-10-25 Loxo Oncology Inc Dosing of a bruton’s tyrosine kinase inhibitor
WO2021133817A1 (en) * 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
TR202002066A2 (tr) * 2020-02-11 2021-08-23 Bahcesehir Ueniversitesi Bcl-2 i̇nhi̇bi̇törü olarak kullanilan yeni̇ küçük terapöti̇k bi̇leşi̇kleri̇n fi̇zi̇k odakli olarak keşfi̇
TR202002072A2 (tr) * 2020-02-11 2021-08-23 Bahcesehir Ueniversitesi Bcl-2 i̇nhi̇bi̇törü olarak kullanilan yeni̇ küçük terapöti̇k bi̇leşi̇kleri̇n fi̇zi̇k odakli olarak keşfi̇
CN115244051B (zh) * 2020-03-12 2024-10-18 南京明德新药研发有限公司 苯并五元环类化合物
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
WO2022089463A1 (zh) * 2020-10-28 2022-05-05 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
WO2023250343A1 (en) 2022-06-21 2023-12-28 Loxo Oncology, Inc. Bcl2 formulations
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
EP1888543B1 (en) 2005-05-24 2012-08-01 Abbott Laboratories Apoptosis promoters
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
JP5684720B2 (ja) 2008-12-05 2015-03-18 アッヴィ・インコーポレイテッド 癌および免疫疾患の治療のためのbcl−2−選択的アポトーシス誘発剤としてのスルホンアミド誘導体
EP3095784A1 (en) 2009-01-19 2016-11-23 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2511264T3 (da) 2009-01-19 2015-06-22 Abbvie Inc Apoptose-inducerende midler til behandling af cancer og immunsygdomme og autoimmune sygdomme
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101723378B1 (ko) * 2009-05-26 2017-04-06 애브비 아일랜드 언리미티드 컴퍼니 암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
MX349533B (es) * 2010-10-29 2017-08-02 Abbvie Inc Dispersiones solidas que contienen un agente inductor de apoptosis.
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102093364B (zh) 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
DK3494115T3 (da) 2016-08-05 2021-01-18 Univ Michigan Regents N-(phenylsulfonyl)benzamidderivater som bcl-2-hæmmere
CN109641897B (zh) 2016-09-01 2021-12-07 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
WO2018127130A1 (en) 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
RS63603B1 (sr) * 2017-04-18 2022-10-31 Shanghai Fochon Pharmaceutical Co Ltd Sredstva za indukciju apoptoze
MX2020007392A (es) 2018-01-10 2020-10-14 Recurium Ip Holdings Llc Compuestos de benzamida.
KR102738032B1 (ko) 2018-04-29 2024-12-05 베이진 엘티디 Bcl-2 억제제

Also Published As

Publication number Publication date
EP4119560A1 (en) 2023-01-18
AU2018255621A1 (en) 2019-10-03
RS63603B1 (sr) 2022-10-31
JP7416365B2 (ja) 2024-01-17
CN110546151A (zh) 2019-12-06
PT3612531T (pt) 2022-10-04
EP3612531A4 (en) 2020-11-11
US20220402913A1 (en) 2022-12-22
EP4119560B1 (en) 2024-06-05
PL3612531T3 (pl) 2022-12-19
KR102630069B1 (ko) 2024-01-26
RU2019136511A (ru) 2021-05-18
ES2927182T3 (es) 2022-11-03
ZA201906011B (en) 2024-01-31
HRP20221158T1 (hr) 2022-12-09
CN116589459A (zh) 2023-08-15
BR112019021434A2 (pt) 2020-05-05
US20200115379A1 (en) 2020-04-16
WO2018192462A1 (en) 2018-10-25
JP7085566B2 (ja) 2022-06-16
CA3057886A1 (en) 2018-10-25
MX2022004304A (es) 2022-05-10
EP3612531A1 (en) 2020-02-26
JP2022119990A (ja) 2022-08-17
MX2019012434A (es) 2019-12-11
TWI791511B (zh) 2023-02-11
AU2022203948B2 (en) 2023-11-02
RU2019136511A3 (hu) 2021-08-19
EP3612531B1 (en) 2022-08-24
SI3612531T1 (sl) 2022-11-30
LT3612531T (lt) 2022-09-26
AU2018255621B2 (en) 2022-03-10
DK3612531T3 (da) 2022-09-05
AU2022203948A1 (en) 2022-06-23
KR20190140910A (ko) 2019-12-20
CN110546151B (zh) 2023-04-28
TW201902893A (zh) 2019-01-16
JP2020516666A (ja) 2020-06-11
US11091478B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
LT3612531T (lt) Apoptozę sukeliančios medžiagos
DK3606954T3 (en) Anti-LAG3-antistoffer
DK3734167T3 (en) Airconditionsystem
DK3499914T3 (en) Høreapparatsystem
DK3700925T3 (en) Hidtil ukendt t-cellereceptor
DK3615457T3 (en) Transportcontainer
DK3401557T3 (en) Træskrue
AU201714106S (en) Mandoline
GB201612093D0 (en) Combination
DK3485765T3 (en) Computerbord
GB201700825D0 (en) Poliovaccine
DK3630041T3 (en) Stimulationsapparat
GB201402267D0 (en) Antibacterial agents
DK3718525T3 (en) Motoriseret asssistancesystem
DK3704866T3 (en) Datatransmissionssystem
EP3718012C0 (en) TROUBLESHOOTING
PT3412667T (pt) Cocristal
GB201616014D0 (en) Combination
GB201610869D0 (en) Combination
DK3425793T3 (en) Tagsystem
DK3618761T3 (en) Intrakorporalt perfusionssystem
DK3351149T3 (en) Syltetøjsfontæne
GB201716492D0 (en) Disclosure
GB201715938D0 (en) Disclosure
GB201715756D0 (en) Disclosure